scispace - formally typeset
Journal ArticleDOI

Diminazene aceturate—An antiparasitic drug of antiquity: Advances in pharmacology & therapeutics

TLDR
A systematic review on diminazene aceturate regarding its pharmacological properties suggested promising new applications such as leishmanicidal, amebicidal,anti-pneumocystis, anti-rheumatoid arthritis, antihypertensive agent and mainly as an activator of angiotensin-converting enzyme 2.
About
This article is published in Pharmacological Research.The article was published on 2015-12-01. It has received 41 citations till now. The article focuses on the topics: Diminazene & Antiparasitic agent.

read more

Citations
More filters
Journal ArticleDOI

Ellagic acid microspheres restrict the growth of Babesia and Theileria in vitro and Babesia microti in vivo

TL;DR: This is the first study to demonstrate the in vitro and in vivo antibabesial action of EA-NPs and thus supports the use of nanoparticles as an alternative antiparasitic agent.
Journal ArticleDOI

Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation.

TL;DR: Experimental studies that have used the off-target effects of the antitrypanosomal agent, diminazene aceturate (DIZE) to activate ACE2 and evaluate its therapeutic potential in comparison with currently available clinical interventions are focused on.
Journal ArticleDOI

The ACE 2 activator diminazene aceturate (DIZE) improves left ventricular diastolic dysfunction following myocardial infarction in rats.

TL;DR: The findings show that chronic DIZE treatment post-MI attenuates the morphofunctional changes induced by MI in rats, and suggest this drug can be used as a therapeutic agent to reduce interstitial fibrosis and diastolic dysfunction after MI.
Journal ArticleDOI

Angiotensin II Receptors - Impact for COVID-19 Severity.

TL;DR: Patients with SARS‐CoV‐2 infection may benefit from therapeutic strategies that activate ACE2‐Ang 1‐7‐Mas axis, such as Ang II receptor blockers (ARBs), ACE inhibitors (ACEIs), Mas receptor agonists and ACE2.
Journal ArticleDOI

17-DMAG inhibits the multiplication of several Babesia species and Theileria equi on in vitro cultures, and Babesia microti in mice.

TL;DR: 17-DMAG is a potent drug for treating piroplamosis and as an option in combination with atovaquone for the treatment of human babesiosis, and the two-drug combination of 17- DMAG with diminazene aceturate (DA) and atOVAquone (AV) showed synergism or addition on in vitro cultures of Babesia and Theileria parasites.
References
More filters
Journal ArticleDOI

Drugs and drug resistance in African trypanosomiasis.

TL;DR: The use of current drugs against human and veterinary African trypanosomiasis, the prevalence, causes and mechanisms of drug resistance and new developments in trypanOSomiasis therapy such as the introduction of nifurtimox and DB289 are discussed.
Journal ArticleDOI

DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors

TL;DR: The results suggest that MGBLs, like camptothecin, abort Topo I reactions by trapping reversible cleavable complexes, and DNA topoisomerase (Topo) I may be a pharmacological target of M GBLs.
Journal ArticleDOI

Current Advances in Detection and Treatment of Babesiosis

TL;DR: The post-genomic era brings a new light on the development of diagnosis methods and new chemotherapy targets for babesiosis, with additional reference to several apicomplexan parasites.
Journal ArticleDOI

Chemotherapy against babesiosis.

TL;DR: Clinical manifestations differ markedly between European and North American diseases, and a combination of clindamycin and quinine is administered as the standard treatment, but also administration of atovaquone-azithromycin is successful.
Related Papers (5)